科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06990 科伦博泰生物-B

休市中 12-12 16:08:09

438.600

+21.000

+5.03%

最高438.600	最低406.400	成交量98.22万
今开420.000	昨收417.600	日振幅7.71%
总市值1,023亿	流通市值713.91亿	总股本2.33亿
成交额4.14亿	换手率0.60%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物-B","latestPrice":438.6,"timestamp":1765526889007,"preClose":417.6,"halted":0,"volume":982214,"delay":0,"floatShares":162769979,"shares":233185969,"eps":-1.3277434523468628,"marketStatus":"休市中","change":21,"latestTime":"12-12 16:08:09","open":420,"high":438.6,"low":406.4,"amount":414244862,"amplitude":0.077107,"askPrice":438.6,"askSize":3200,"bidPrice":437.2,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-3.5325290584536857,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765762200000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":417.6,"openAndCloseTimeList":[[1765503000000,1765512000000],[1765515600000,1765526400000]],"volumeRatio":1.5051016737325902,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990/tweets","defaultTab":"tweets","newsList":[{"id":"2590508581","title":"博度曲妥珠单抗：已获批二线及以上治疗乳腺癌，涵盖三线适应症人群","url":"https://stock-news.laohu8.com/highlight/detail?id=2590508581","media":"医药笔记","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590508581?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:17","pubTimestamp":1765531030,"startTime":"0","endTime":"0","summary":"值得注意的是，今年10月，博度曲妥珠单抗已获批治疗二线及以上HER2 阳性乳腺癌，成为首个覆盖该适应症二线及以上全人群的国产HER2 ADC药物，为中国晚期 HER2 阳性乳腺癌患者带来全新治疗选择。据悉，在博度曲妥珠单抗进行上市申请申报的过程中，先后提交了两个适应症申请：分别针对三线及以上，以及二线及以上HER2阳性乳腺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212174847a44490e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212174847a44490e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2590085555","title":"国产之光，科伦博泰HER2 ADC突围二线及以上全人群HER2阳性乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2590085555","media":"药械Talks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590085555?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:36","pubTimestamp":1765528617,"startTime":"0","endTime":"0","summary":"根据获批适应症，博度曲妥珠单抗将用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌患者。虽然在博度曲妥珠单抗之前，已有两款国产HER2 ADC拿到上市许可。所以，博度曲妥珠单抗是首个真正意义上实现HER2阳性乳腺癌二线及以上治疗全面覆盖的国产HER2 ADC。要进一步说明的是，在博度曲妥珠单抗进行NDA申报的过程中，先后提交了两个适应症申请：分别针对三线及以上，以及二线及以上HER2阳性乳腺癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212164453a4446707&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212164453a4446707&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2590371508","title":"科伦药业控股子公司科伦博泰拟推2025年股份激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2590371508","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590371508?lang=zh_cn&edition=full","pubTime":"2025-12-12 13:30","pubTimestamp":1765517418,"startTime":"0","endTime":"0","summary":"中访网数据  四川科伦药业股份有限公司于12月12日发布公告，其控股子公司四川科伦博泰生物医药股份有限公司计划实施2025年股份激励计划。科伦药业表示，即使按此上限全额发行，其持有科伦博泰的股权比例也不会发生重大变化，科伦博泰仍为其控股子公司。目前，该激励计划已获得科伦博泰董事会审议通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212134240a4440641&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212134240a4440641&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2590247523","title":"中金：维持科伦博泰生物-B(06990)跑赢行业评级 目标价550港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590247523","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590247523?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:16","pubTimestamp":1765502219,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑到科伦博泰生物-B授权首付款收入，基本保持2026年归母净利润预测不变。该行维持跑赢行业评级，基于DCF模型，维持目标价550港币，较当前股价有33.4%的上行空间。该行认为SKB105作为临床前阶段的新兴靶点ADC资产，本次达成对外授权，给公司带来较好的现金流入的同时也助力其临床开发路径进入快车道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990"],"gpt_icon":0},{"id":"2590459693","title":"每日卖空追踪 | 科伦博泰生物-B 12月11日卖空量成交4.07万股，卖空比例为11.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590459693","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590459693?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:30","pubTimestamp":1765441836,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间12月11日，涨1.31%，卖空量成交4.07万股，较上一交易日减少81.75%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163727979c697a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163727979c697a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2590627805","title":"【券商聚焦】天风证券维持科伦博泰生物-B(06990)“买入”评级 指公司核心产品商业化进程顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2590627805","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590627805?lang=zh_cn&edition=full","pubTime":"2025-12-11 14:42","pubTimestamp":1765435355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 天风证券发研报指，科伦博泰生物-B Crescent达成合作，共同开发及商业化新型肿瘤治疗手段，合作涉及科伦博泰的一款靶向整合素β6并以拓扑异构酶抑制剂为载荷ADC药物SKB105，以及Crescent的一款PD-1xVEGF双特异性抗体CR-001。如Crescent在近期发生控制权变更或与第三方达成分许可安排，科伦博泰亦有资格收取额外对价。维持“买入”评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971386","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","601162"],"gpt_icon":0},{"id":"2590568156","title":"港股异动 | 科伦博泰生物-B(06990)涨超4% ITGB6等两款候选药于明年一季度开展I/II期单药治疗临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2590568156","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590568156?lang=zh_cn&edition=full","pubTime":"2025-12-11 10:02","pubTimestamp":1765418557,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B涨超4%，截至发稿，涨3.69%，报427.4港元，成交额1831.69万港元。这两款候选药物正在开发用于治疗实体瘤，预计于2026年第一季度开展I/II期单药治疗临床试验。天风证券指出，科伦博泰生物与Crescent合作内容包括分别推进两款候选药物的单药治疗开发，并共同评估CR-001与SKB105的联用疗法。如Crescent在近期发生控制权变更或与第三方达成分许可安排，科伦博泰生物亦有资格收取额外对价。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380221.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0},{"id":"2590596925","title":"受美联储降息消息提振，恒生医药强势反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2590596925","media":"云掌财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590596925?lang=zh_cn&edition=full","pubTime":"2025-12-11 09:53","pubTimestamp":1765417997,"startTime":"0","endTime":"0","summary":"美联储如期降息25bp，港股市场迎来反弹行情，聚焦创新药的恒生生物科技指数涨超1%，在关键指数中涨幅居前，跟踪该指数规模最大的恒生医药ETF（159892）涨近1%，康方生物、科伦博泰生物、晶泰控股等涨幅靠前。从二级市场来看，11月28日，恒生生物科技指数期货正式推出。恒生指数公司表示，随着指数产品的生态系统成熟，期货成交将会趋于活跃，也会进一步提升该板块的成交活跃度。从政策层面来看，国家医保目录及商保目录已于近期公布，将于2026年1月1日起正式执行。东方证券认为，医保政策坚定支持创新，降价幅度已不构成主要矛盾，医保政策风险下降，相关配套政策有望逐步落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211095321979bc171&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211095321979bc171&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1515","09939","BK1574","09926","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2590512615","title":"科伦博泰生物-B：SKB2641L肺癌III期成功 SKB105达成授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2590512615","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590512615?lang=zh_cn&edition=full","pubTime":"2025-12-11 00:00","pubTimestamp":1765382400,"startTime":"0","endTime":"0","summary":"近日，公司宣布：1）TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗1L治疗PD-L1 阳性非小细胞肺癌的国内III期临床OptiTROP-Lung05 达到主要终点。2）公司与Crescent Biopharma达成合作，将ITGB6 ADCSKB105 海外权益以8,000 万美元首付款和高达12.5 亿美元的里程碑授予Crescent，并以2,000 万美元首付款和高达3,000 万美元里程碑引进Crescent PD-1 x VEGF双抗CR-001 的中国权益。根据公司公告，公司预计此次合作的两款药物将于1Q26 开展I/II期单药临床，同时双方有权开发引进管线的联用方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211184208a6995d1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211184208a6995d1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2590596999","title":"科伦博泰生物-B将于2025年12月31日召开第一次特别股东大会 股东名册12月24日至31日暂停过户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590596999","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590596999?lang=zh_cn&edition=full","pubTime":"2025-12-10 20:39","pubTimestamp":1765370381,"startTime":"0","endTime":"0","summary":"金吾财讯 | 四川科伦博泰生物医药股份有限公司公布，为确定有权出席及投票于2025年12月31日举行的第一次特别股东大会的股东身份，公司股东名册将于2025年12月24日至12月31日暂停办理股份过户登记手续。于2025年12月31日名列股东名册的股东方有权出席及投票。未登记股东须于2025年12月23日下午4时30分或之前，将过户文件连同有关股票交回公司H股股份过户登记处香港中央证券登记有限公司办理登记手续，方可出席大会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512102116049535aff8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512102116049535aff8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0196878994.USD","06990","BK1161"],"gpt_icon":0},{"id":"2590407563","title":"超13亿美元！不是出海，是换仓！拆解科伦博泰与Crescent的资源置换","url":"https://stock-news.laohu8.com/highlight/detail?id=2590407563","media":"制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590407563?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:22","pubTimestamp":1765264973,"startTime":"0","endTime":"0","summary":"2025年12月4日，科伦博泰与Crescent Biopharma达成了一项总金额超 13 亿美元的战略合作。此时，Crescent Biopharma旗下的CR-001提供了一个可行的解决方案。Crescent在公开材料中指出，CR-001在设计上旨在实现与已上市PD-1/VEGF双抗相似的协同药理学特性。而本次与Crescent的合作，展示了一种更灵活的 “资源置换” 思路。科伦博泰通过此次交易，在输出ADC技术的同时，引进了关键的免疫治疗资产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209152259a43d1546&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209152259a43d1546&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2589358055","title":"每日卖空追踪 | 科伦博泰生物-B 12月08日卖空量成交6.99万股，卖空比例为11.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589358055","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589358055?lang=zh_cn&edition=full","pubTime":"2025-12-08 16:30","pubTimestamp":1765182636,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间12月08日，跌3.09%，卖空量成交6.99万股，较上一交易日增加13.11%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163620a43afbb5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208163620a43afbb5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2589333580","title":"国金证券：从2025医保谈判看行业风向 成功率提升创新导向持续强化","url":"https://stock-news.laohu8.com/highlight/detail?id=2589333580","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589333580?lang=zh_cn&edition=full","pubTime":"2025-12-08 11:51","pubTimestamp":1765165873,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，2025年12月7日，国家医保局发布《2025新版基本医保药品目录》及首个《商业健康保险创新药品目录》，新版药品目录自2026年1月1日起正式执行。得益于创新药突出的临床价值，2025年新药谈判成功率较同期实现显著提升，此类药品预计将收获良好的谈判结果。CAR-T疗法因价格昂贵，曾多次无缘基本医保目录，此次全部成功纳入商保，具体协商价格暂未披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208115342a43a7cc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208115342a43a7cc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348827113.USD","LU0561508036.HKD","LU0417516571.SGD","06978","LU2476274308.USD","LU0348766576.USD","09926","LU1961090484.USD","LU0348783233.USD","IE00B543WZ88.USD","LU0417516738.SGD","BK1574","LU0540923850.HKD","02162","BK1161","IE00BPRC5H50.USD","LU1794554557.SGD","LU2399975544.HKD","LU2476274720.SGD","LU0634319403.HKD","LU0348735423.USD","LU2488822045.USD","LU2778985437.USD","LU0348784397.USD","06990","IE00B5MMRT66.SGD","LU0348767384.USD","LU0417516902.SGD","01276","LU0348825331.USD","LU1720050803.USD"],"gpt_icon":0},{"id":"2589845988","title":"每日卖空追踪 | 科伦博泰生物-B 12月05日卖空量成交2.66万股，卖空比例为7.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589845988","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589845988?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:30","pubTimestamp":1764923435,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间12月05日，涨2.45%，卖空量成交2.66万股，较上一交易日减少20.6%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205163605a4ce67dd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205163605a4ce67dd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0196878994.USD","06990"],"gpt_icon":0},{"id":"2589845670","title":"科伦博泰生物-B12月05日获主力加仓246.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2589845670","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589845670?lang=zh_cn&edition=full","pubTime":"2025-12-05 16:15","pubTimestamp":1764922556,"startTime":"0","endTime":"0","summary":"12月05日, 科伦博泰生物-B股价涨2.45%，报收460.00元，成交金额1.7亿元，换手率0.23%，振幅3.39%，量比1.24。科伦博泰生物-B今日主力资金净流入246.9万元，上一交易日主力净流入232.9万元。该股近5个交易日上涨0.79%，主力资金累计净流入2616.1万元，其中3个交易日为股价下跌时净流入；近20日主力资金累计净流入1300.7万元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120516213997917a51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025120516213997917a51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2589853098","title":"智通港股早知道 | 因大宗商品供应线路被扰乱 航运价格飙升467%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589853098","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589853098?lang=zh_cn&edition=full","pubTime":"2025-12-05 07:27","pubTimestamp":1764890871,"startTime":"0","endTime":"0","summary":"航运价格飙升467% 因大宗商品供应线路被扰乱12月3日，波罗的海干散货指数报2845点，创下2023年12月6日以来新高水平，单日涨幅达9.42%，为近两个月最大单日涨幅。四位知情人士透露，摩科瑞已于12月2日取消了仓单，预定提取LME存放在亚洲仓库中的、超过4万吨铜金属。受让方与转让方于2025年12月4日分别签署收购合同。收购事项完成后，标的公司将成为本公司的间接非全资附属公司，而其财务业绩将综合计入本公司的财务报表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02676","BK1161","LU0196878994.USD","161715","000979.SH","06990"],"gpt_icon":0},{"id":"2588088622","title":"科伦博泰生物-B(06990)与Crescent Biopharma建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段","url":"https://stock-news.laohu8.com/highlight/detail?id=2588088622","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588088622?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:43","pubTimestamp":1764848616,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 公布，公司与Crescent Biopharma,Inc.及其全资子公司Crescent Biopharma Operating Company,LLC已建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段。Crescent则授予公司在大中华地区研究、开发、生产和商业化CR-001的独家权利。此次合作包括开发两款候选药物的单药疗法，以及评估CR-001与SKB105的联用疗法。若Crescent近期发生控制权变更或与第三方签订分许可协议，公司亦有资格向Crescent收取额外款项。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","LU0196878994.USD","06990","LU0329678337.USD","LU0737861772.HKD","BK1209","06078","LU2488822045.USD","LU0329678170.USD"],"gpt_icon":0},{"id":"1114300938","title":"科伦博泰生物-B公司将获得8000万美元的预付款及高达12.5亿美元的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1114300938","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114300938?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:36","pubTimestamp":1764848173,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B公司将获得8000万美元的预付款及高达12.5亿美元的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"1115537632","title":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1115537632","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115537632?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847944,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1064130708.USD","LU1979443071.USD","002422","CBIO","BK0060","BK1161","LU2148510915.USD","06990","LU1934453819.USD","BK0239","LU0196878994.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"1126942018","title":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1126942018","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126942018?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847941,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002422","06990","BK0239","LU0196878994.USD","LU1064130708.USD","BK1161","CBIO","LU1064131003.USD","BK4139","LU2148510915.USD","LU1934453819.USD","BK0060","LU1979443071.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0465},{"period":"1month","weight":0.0139},{"period":"3month","weight":-0.1341},{"period":"6month","weight":0.264},{"period":"1year","weight":1.3084},{"period":"ytd","weight":1.6859}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事新药业务的研发、生产和销售的中国公司。该公司主要从事肿瘤学、免疫学及其他治疗领域的创新药物的研发、制造及商业化。该公司的产品为抗体药物偶联物（ADC）SKB264及A166。该公司产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等非肿瘤疾病的治疗。","exchange":"SEHK","name":"科伦博泰生物-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物-B,06990,科伦博泰生物-B股票,科伦博泰生物-B股票老虎,科伦博泰生物-B股票老虎国际,科伦博泰生物-B行情,科伦博泰生物-B股票行情,科伦博泰生物-B股价,科伦博泰生物-B股市,科伦博泰生物-B股票价格,科伦博泰生物-B股票交易,科伦博泰生物-B股票购买,科伦博泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}